Mitchell E. Horwitz
Experienced in Marginal Zone Lymphoma (MZL)

Dr. Mitchell E. Horwitz

Infectious Disease | Transplant Surgery
Duke Health
Duke Adult Blood And Marrow Transplant Clinic
2400 Pratt St, 
Durham, NC 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
32 Years of Experience

Experienced in Marginal Zone Lymphoma (MZL)
Duke Health
Duke Adult Blood And Marrow Transplant Clinic
2400 Pratt St, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

People in need of a bone marrow transplantation can often be scared or intimidated by what is ahead of them -- my goal, when seeing a new patient, is to devote all the time and effort that is needed to address these emotions. My hope is that after this visit, my patient will feel reassured and hopeful that the Duke team of providers will do all that it can to restore them to health, and allow them to return to their lives.

Dr. Horwitz is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Transplant Surgery
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Med, Medical Oncology
Fellowships
Hematology and Oncology, National Institutes of Health (Maryland)
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Duke Adult Blood and Marrow Transplant Clinic
2400 Pratt St, Durham, NC 27705
Call: 919-668-1002

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Enrollment Status: Recruiting
Publish Date: November 28, 2025
Intervention Type: Procedure, Biological
Study Drug: NRTX-1001
Study Phase: Phase 3
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Biological
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: Glasdegib
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: February 13, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation
A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: June 05, 2017
Intervention Type: Biological
Study Phase: Phase 1
View 10 Less Clinical Trials

112 Total Publications

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
View All 112 Publications
Similar Doctors
Cristina D. Gasparetto
Experienced in Marginal Zone Lymphoma (MZL)
Dr. Cristina D. Gasparetto
Infectious Disease | Hematology | Transplant Surgery
Experienced in Marginal Zone Lymphoma (MZL)
Dr. Cristina D. Gasparetto
Infectious Disease | Hematology | Transplant Surgery

Duke Hematologic Malignancies Clinic

2400 Pratt St, 
Durham, NC 
 (0.1 miles away)
919-684-8964
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

The Division of Cellular Therapy does bone marrow transplants and stem cell transplants for patients with different types of blood cancers. Specifically, I see patients with multiple myeloma or other plasma cell issues like amyloidosis. Many of the cases in my clinic are difficult. So I spend a lot of time talking with my patients, explaining the disease when they come as new patients and talking about the complexity of the disease, because it’s important that they understand what to ask their physicians here at Duke and at home. There’s no standard treatment for myeloma. We have different options – continuation of therapy, immediate transplant or transplant later. I like to explain to patients why I favor a certain treatment approach and why I think it would be the best approach for them. Dr. Gasparetto is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Colonoscopy.

Taewoong Choi
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Taewoong Choi
Hematology Oncology | Hematology | Transplant Surgery
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Taewoong Choi
Hematology Oncology | Hematology | Transplant Surgery

Duke Blood Cancer Center

2400 Pratt St, 
Durham, NC 
 (0.1 miles away)
919-684-8964
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Since studying basic immunology prior to beginning my clinical training, I have been deeply interested in applying immunological perspective for the treatment of cancers including hematologic malignancies. Interestingly emerging immunotherapies showed very promising results in recent years. In my clinic, I treat patients with multiple myeloma which is one type of cancer arising from plasma cells. My research will focus on developing early phase clinical protocols utilizing novel cellular therapy approach and also improving the outcomes of blood and marrow transplantation. My ultimate goal is to provide better treatment options than the current standard approach to patients. Dr. Choi is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Nelson J. Chao
Experienced in Marginal Zone Lymphoma (MZL)
Dr. Nelson J. Chao
Oncology | Transplant Surgery
Experienced in Marginal Zone Lymphoma (MZL)
Dr. Nelson J. Chao
Oncology | Transplant Surgery

Duke Adult Blood And Marrow Transplant Clinic

2400 Pratt St, 
Durham, NC 
 (0.1 miles away)
919-668-1002
Languages Spoken:
English, Portuguese
See accepted insurances
Accepting New Patients
Offers Telehealth

What makes Duke Health unique in bone marrow transplants is its holistic approach. We take care of the disease -- which is important, because these are very serious, potentially fatal diseases. But at the same time, we pay attention to patients’ emotional and psychological well-being in addition to their physical well-being. And not only for patients but also the whole family, because the caregivers and other parts of the family need attention as well. I wanted to go into medicine, because it was a great way to interact and take care of patients. In my mind, cancer is one of two diseases within internal medicine where you can actually cure people. The best part of bone marrow transplant is that the time between the laboratory and the patient is short. Patients who need a transplant tend to be relatively sick and in need of new therapies. That’s been very intellectually challenging and fun. Dr. Chao is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

VIEW MORE MARGINAL ZONE LYMPHOMA (MZL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Horwitz's expertise for a condition
ConditionClose
    • Distinguished
    • Chronic Graft Versus Host Disease (cGvHD)
      Dr. Horwitz is
      Distinguished
      . Learn about Chronic Graft Versus Host Disease (cGvHD).
      See more Chronic Graft Versus Host Disease (cGvHD) experts
    • Advanced
    • Bone Marrow Transplant
      Dr. Horwitz is
      Advanced
      . Learn about Bone Marrow Transplant.
      See more Bone Marrow Transplant experts
    • Classical Hodgkin Lymphoma
      Dr. Horwitz is
      Advanced
      . Learn about Classical Hodgkin Lymphoma.
      See more Classical Hodgkin Lymphoma experts
    • Relapsed Refractory Multiple Myeloma (RRMM)
      Dr. Horwitz is
      Advanced
      . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
      See more Relapsed Refractory Multiple Myeloma (RRMM) experts
    • Smoldering Multiple Myeloma
      Dr. Horwitz is
      Advanced
      . Learn about Smoldering Multiple Myeloma.
      See more Smoldering Multiple Myeloma experts
    • T-Cell Lymphoma
      Dr. Horwitz is
      Advanced
      . Learn about T-Cell Lymphoma.
      See more T-Cell Lymphoma experts
    • Experienced
    • Adult T-Cell Leukemia
      Dr. Horwitz is
      Experienced
      . Learn about Adult T-Cell Leukemia.
      See more Adult T-Cell Leukemia experts
    • Bone Marrow Aspiration
      Dr. Horwitz is
      Experienced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Cytomegalic Inclusion Disease
      Dr. Horwitz is
      Experienced
      . Learn about Cytomegalic Inclusion Disease.
      See more Cytomegalic Inclusion Disease experts
    • Cytomegalovirus Infection
      Dr. Horwitz is
      Experienced
      . Learn about Cytomegalovirus Infection.
      See more Cytomegalovirus Infection experts
    • Febrile Neutropenia
      Dr. Horwitz is
      Experienced
      . Learn about Febrile Neutropenia.
      See more Febrile Neutropenia experts
    • Marginal Zone Lymphoma (MZL)
      Dr. Horwitz is
      Experienced
      . Learn about Marginal Zone Lymphoma (MZL).
      See more Marginal Zone Lymphoma (MZL) experts
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.